Cargando…

B Cell Tolerance and Targeted Therapies in SLE

Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disease of high clinical and molecular heterogeneity, and a relapsing-remitting pattern. The disease is currently without cure and more prevalent in women. B cell tolerance and production of autoantibodies are critical mechanisms th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parodis, Ioannis, Long, Xuan, Karlsson, Mikael C. I., Huang, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573616/ https://www.ncbi.nlm.nih.gov/pubmed/37834911 http://dx.doi.org/10.3390/jcm12196268

Ejemplares similares

B cell alterations during BAFF inhibition with belimumab in SLE
por: Ramsköld, Daniel, et al.
Publicado: (2018)

B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools
por: Parodis, Ioannis, et al.
Publicado: (2022)

Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case–control study
por: Samuelsson, Isak, et al.
Publicado: (2021)

Mechanisms of B cell autoimmunity in SLE
por: Dörner, Thomas, et al.
Publicado: (2011)

Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE
por: Borg, Alexander, et al.
Publicado: (2021)

B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
por: Parodis, Ioannis, et al.
Publicado: (2020)

Targeted Therapy for SLE—What Works, What Doesn’t, What’s Next
por: Venturelli, Veronica, et al.
Publicado: (2023)

Editorial: Clinical, Molecular and Adverse Responses to B-Cell Therapies in Autoimmune Disease
por: Sciascia, Savino, et al.
Publicado: (2022)

Regulation of B Cell Responses in SLE by Three Classes of Interferons
por: Domeier, Phillip P., et al.
Publicado: (2021)

Age-Associated B Cells (ABCs) in the Prognosis, Diagnosis and Therapy of Systemic Lupus Erythematosus (SLE)
por: Sachinidis, Athanasios, et al.
Publicado: (2020)

Targeting Toll-Like Receptors for Treatment of SLE
por: Horton, Christopher G., et al.
Publicado: (2010)

Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?
por: Parodis, Ioannis, et al.
Publicado: (2022)

Genes Associated with SLE Are Targets of Recent Positive Selection
por: Ramos, Paula S., et al.
Publicado: (2014)

Targeting DORIS Remission and LLDAS in SLE: A Review
por: Parra Sánchez, Agner R., et al.
Publicado: (2023)

Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New
por: Basta, Fabio, et al.
Publicado: (2020)

Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State
por: Hua, Nicole, et al.
Publicado: (2023)

SLE: reconciling heterogeneity
por: Lockshin, Michael D, et al.
Publicado: (2019)

Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway
por: Oon, Shereen, et al.
Publicado: (2016)

BTLA Expression and Function Are Impaired on SLE B Cells
por: Wiedemann, Annika, et al.
Publicado: (2021)

Therapeutic Strategies for SLE Involving Cytokines: Mechanism-Oriented Therapies Especially IFN-γ Targeting Gene Therapy
por: Hayashi, Toshiharu
Publicado: (2010)

B cells at the adaptive-innate immune system interface in SLE
por: Anolik, JH, et al.
Publicado: (2012)

Cell-bound complement activation products in SLE
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2017)

Chimeric maternal cells as T lymphocyte targets in pediatric SLE
por: Stevens, Anne M, et al.
Publicado: (2012)

IgE in the Pathogenesis of SLE: From Pathogenic Role to Therapeutic Target
por: Lamri, Yasmine, et al.
Publicado: (2020)

Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver’s Seat in Their Disease Monitoring?
por: Parodis, Ioannis, et al.
Publicado: (2022)

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments
por: Touma, Zahi, et al.
Publicado: (2017)

“P(2)RY(8)-son” break of tolerance promotes SLE
por: Tusseau, Maud, et al.
Publicado: (2021)

B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design
por: Reddy, Venkat, et al.
Publicado: (2013)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
por: Lorenzo-Vizcaya, Ana, et al.
Publicado: (2020)

Assessing the Function of the ZFP90 Variant rs1170426 in SLE and the Association Between SLE Drug Target and Susceptibility Genes
por: Zhu, Tingting, et al.
Publicado: (2021)

CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function
por: Bhamidipati, Kartik, et al.
Publicado: (2021)

Microparticles as antigenic targets in human and murine SLE
por: Ullal, Anirudh, et al.
Publicado: (2012)

Effect of targeted nursing applied to SLE patients
por: ZHANG, XIANGYING, et al.
Publicado: (2016)

Autoantibodies in SLE: Specificities, Isotypes and Receptors
por: Dema, Barbara, et al.
Publicado: (2016)

Dysregulation of immunity in COVID-19 and SLE
por: Hejazian, Seyyed Sina, et al.
Publicado: (2022)

Epigenetic programming underpins B cell dysfunction in human SLE
por: Scharer, Christopher D., et al.
Publicado: (2019)

Clinical impact of biologic therapy in the treatment of SLE
por: Wallace, Daniel J
Publicado: (2013)

Patient perceptions and preferences of biologic therapies in SLE
por: Lim, S Sam, et al.
Publicado: (2019)

Corrigendum: Assessing the Function of the ZFP90 Variant rs1170426 in SLE and the Association Between SLE Drug Target and Susceptibility Genes
por: Zhu, Tingting, et al.
Publicado: (2022)

Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8vdld7li7hgleadbbfbg04j5v2